.Margaret,This is from the Annual Report (page 11) issued 28...

.Margaret,

This is from the Annual Report (page 11) issued 28 September, the report you refer to was issued 12 September

ArTiMist®: malaria ArTiMist® is the world’s first sublingual spray for the treatment of p. falciparum severe paediatric malaria.

The active pharmaceutical ingredient in ArTiMist is artemether, which is a widely used anti-malarial and is currently administered by infusion or orally in a tablet form.

ArTiMist was designed with a child in mind: a child living in a challenging environment where healthcare resources can be very scarce and time is of the essence.

The simple sublingual spray could be particularly valuable as a pre-referral treatment when children first show signs of a malaria-like fever, before being referred to hospital. ArTiMist is owned and managed by SUDA’s subsidiary company, Malaria Research Company Pty Ltd (MRC).

SUDA has received positive responses from the reviewers of the Marketing Authorisation Application at the TGA. The application was accepted for review in April 2017.

Subject to some outstanding questions, which SUDA and its contractors are addressing,
Marketing Approval is anticipated by June 2019

The Company continues its discussions with pharmaceutical companies in relation to the sale or licence of ArTiMist, as well as with potential distributors that have a strong franchise in anti-malarials in Sub-Saharan Africa. These two options are not mutually exclusive